JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: A randomized controlled trial

Trials

Volumn 11, Issue , 2010, Pages

  Cao, Hongbo ^a   Ren, Ming ^a   Guo, Liping ^a   Shang, Hongcai ^a,b   Zhang, Junhua ^b   Song, Yuzhen ^a   Wang, Hui ^a   Wang, Baohe ^a   Li, Xiantao ^a   Hu, Jing ^b   Wang, Xuemei ^c   Wang, Dehui ^d   Chen, Jianzong ^e   Li, Shuanglei ^f   Chen, Liming ^g  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Evidence Based Medicine Centre of Tianjin   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion   (China)

^e FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^f The First Affiliated Hospital of Guangxi College of TCM   (China)

^g TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; JINQI JIANGTANG; PLACEBO; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; JINQI JIANTANG;

ARTICLE; CHINA; CHINESE MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; BLOOD; DISEASE COURSE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PATENT; TIME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHINA; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PATENTS AS TOPIC; PREDIABETIC STATE; RESEARCH DESIGN; TABLETS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951150624     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-27     Document Type: Article

References (19)

1. Pan CY, Lu JM, Tian H, Kong XT, Lu XP, Yao C, Jiang CE, Deng XX, Wang SY, Zhang XL, Wang ZS, Cui L. Study of the prevalence of diabetes mellitus in adults in the shougang corporation in Beijing. Diabetes Med 1996, 13:663-68.
2. Pan Xiao Ren, LI Guang Wei, Hu Ying Hua, et al. Diet and exercise intervention in the treatment of diabetes incidence rate of 530 cases of impaired glucose tolerance 6 years prospective observation of the crowd. Chinese Journal of internal medicine 1995, 34:108-111.
3. Xing X. The life style intervention treats IGT the feasibility and the curative effect and the appraisal. Liaoning practical diabetes magazine 2003, 11:7-8.
4. Lu JM. Abnormal glucose metabolism with metabolic syndrome risk investigation and analysis - discussion suited to the Chinese population with metabolic syndrome diagnostic criteria. Chinese Journal of Diabetes 2004, 12:340-343.
5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, . STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-94. 10.1001/jama.290.4.486, 12876091, STOP-NIDDM Trial Research Group.
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, . Diabetes Prevention Program Research Group Diabetes prevention program research group reduction in the incidence of type 2 diabetes with lifestyle intervention metformin. N Engl J Med 2002, 346:393-403. 10.1056/NEJMoa012512, 1370926, 11832527, Diabetes Prevention Program Research Group.
7. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Controlled Clinical Trials 1998, 19:217-31. 10.1016/S0197-2456(97)00151-7, 9551285.
8. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) trial investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096-105. 10.1016/S0140-6736(06)69420-8, 16997664, The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) trial investigators.
9. The DREAM trial investigators Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551-62. 10.1056/NEJMoa065061, 16980380, The DREAM trial investigators.
10. Chan KL. On the treatment of diabetes in Chinese medicine research and development. Foreign Medical endocrinology fascicle 2004, 24:150.
11. Yan KL. Astronavigation, and so on. Beijing Chinese medicine university masters graduation thesis 2007,
12. Zhou ZN. Jinqi Jiangtang tablet on impaired glucose tolerance to explore the efficacy. Practical Journal of Investigational drug 2002, 18:3-4.
13. Shen ZF, Xie MZ, Liu HF. Influence of JinQI-jiangtang tablet on animals of glycometabolism. Traditional Chinese Drug Research & Clinical Pharmacology 1996, 7(2):24-26.
14. Mechanism of Chinese goldthread on reduction of blood sugar. Shandong Journal of Traditional Chinese Medicine 2005, 11:688.
15. Ji LL. The herbalism analysis of berberine on diabetes. J Sichuan Tradit Med 1999, 11:17-19.
16. Xie MZ, Liu HF. Influence of JiQi-Jiangtang on blood fat, insulin resistance, immune function of animals. Traditional Chinese Drug Research & Clinical Pharmacology 1997, 1:23-24.
17. Shen ZF. Pharmacological base of JinQi-Jiangtang tablet on diabetes. Foreign Medical Sciences Section of Endocrine 2004, 24:215-216.
18. Gu WY. Clinical evaluation of efficacy of Jinqi hypoglycemic tablet with Gliclazide in the treatment of type 2 diabetes mellitus. Journal of Tianjin Medical University 2004, 1:87-89.
19. Zhang RR, Liu Y. The influence of JinQi-Jiangtang tablet on excretion rate of microalbumin of IGT patients. Tianjing Medical Journal 2005, 33:301-30.